论文信息 - A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors - 字舞流文

A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors

Steve Y. Cho | J. Maris | P. Adamson | F. Balis | B. Widemann | S. Cohn | A. Krivoshik | E. Fox | D. Medina | A. Hagey | A. Goodwin | K. Meek | W. Goodspeed | Marie Kromplewski | M. Fouts